A Multicenter, Randomized, Controlled Phase III Clinical Study of Docetaxel for Injection (Albumin-bound) Versus Taxotere in Gastric Cancer
Latest Information Update: 18 Nov 2024
Price :
$35 *
At a glance
- Drugs Docetaxel (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors CSPC ZhongQi Pharmaceutical Technology
- 26 Sep 2024 Status changed from not yet recruiting to recruiting.
- 11 Mar 2024 New trial record